180 related articles for article (PubMed ID: 19387707)
1. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore.
Fong RK; Low J; Koh TH; Kurup A
Eur J Clin Microbiol Infect Dis; 2009 Aug; 28(8):983-7. PubMed ID: 19387707
[TBL] [Abstract][Full Text] [Related]
2. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
3. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
Howden BP
Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.
Zhang S; Sun X; Chang W; Dai Y; Ma X
PLoS One; 2015; 10(8):e0136082. PubMed ID: 26287490
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study.
Yamakawa J; Aminaka M; Okuzumi K; Kobayashi H; Katayama Y; Kondo S; Nakamura A; Oguri T; Hori S; Cui L; Ito T; Jin J; Kurosawa H; Kaneko K; Hiramatsu K
J Infect Chemother; 2012 Jun; 18(3):406-9. PubMed ID: 22033576
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
Gomes DM; Ward KE; LaPlante KL
Pharmacotherapy; 2015 Apr; 35(4):424-32. PubMed ID: 25884530
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China.
Wang Y; Hu YJ; Ai XM; Xu HT; Sun TY
Chin Med J (Engl); 2013 Feb; 126(3):505-9. PubMed ID: 23422115
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital.
da Costa TM; Morgado PG; Cavalcante FS; Damasco AP; Nouér SA; Dos Santos KR
PLoS One; 2016; 11(8):e0160506. PubMed ID: 27575698
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units.
Hu HC; Kao KC; Chiu LC; Chang CH; Hung CY; Li LF; Liu TP; Lin LC; Chen NH; Huang CC; Yang CT; Lu JJ
BMC Infect Dis; 2015 Oct; 15():444. PubMed ID: 26497595
[TBL] [Abstract][Full Text] [Related]
11. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
[TBL] [Abstract][Full Text] [Related]
12. Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.
Khatib R; Riederer K; Sharma M; Shemes S; Iyer SP; Szpunar S
J Clin Microbiol; 2015 Nov; 53(11):3543-6. PubMed ID: 26311860
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin-intermediate Staphylococcus aureus selected during vancomycin therapy of experimental endocarditis are not detected by culture-based diagnostic procedures and persist after treatment arrest.
Moreillon P; Bizzini A; Giddey M; Vouillamoz J; Entenza JM
J Antimicrob Chemother; 2012 Mar; 67(3):652-60. PubMed ID: 22167243
[TBL] [Abstract][Full Text] [Related]
16. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.
Howden BP; Smith DJ; Mansell A; Johnson PD; Ward PB; Stinear TP; Davies JK
BMC Microbiol; 2008 Feb; 8():39. PubMed ID: 18304359
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections.
van Hal SJ; Jones M; Gosbell IB; Paterson DL
PLoS One; 2011; 6(6):e21217. PubMed ID: 21713004
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
Srisrattakarn A; Chaiyapoke C; Booncharoen S; Wongthong S; Chanawong A; Tippayawat P; Tavichakorntrakool R; Lulitanond A
Turk J Med Sci; 2021 Aug; 51(4):2150-2158. PubMed ID: 33705643
[TBL] [Abstract][Full Text] [Related]
19. Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.
Riederer K; Shemes S; Chase P; Musta A; Mar A; Khatib R
J Clin Microbiol; 2011 Jun; 49(6):2147-50. PubMed ID: 21490190
[TBL] [Abstract][Full Text] [Related]
20. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
Howden BP; Johnson PD; Ward PB; Stinear TP; Davies JK
Antimicrob Agents Chemother; 2006 Sep; 50(9):3039-47. PubMed ID: 16940100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
